Related Experiment Video
Updated: Feb 7, 2026

Modeling Neural Immune Signaling of Episodic and Chronic Migraine Using Spreading Depression In Vitro
Published on: June 13, 2011
Emerging Treatments in Episodic Migraine
Kate W Grimsrud1, Rashmi B Halker Singh2
1Department of Neurology, Mayo Clinic Arizona, Scottsdale, AZ, USA. grimsrud.kate@mayo.edu.
New treatments for episodic migraine are emerging, including novel medications like CGRP monoclonal antibodies and advanced neuromodulation devices. These innovations promise improved migraine management and reduced patient disability.
Area of Science:
- Neurology
- Pharmacology
- Medical Devices
Background:
- Episodic migraine presents a significant challenge in neurological care.
- Understanding migraine pathophysiology has spurred new therapeutic investigations.
Purpose of the Study:
- To review and describe recent and emerging treatment options for episodic migraine.
- Evaluate novel pharmacologic and non-pharmacologic interventions.
Main Methods:
- Literature review of recent advances in migraine treatment.
- Analysis of emerging pharmacologic agents and neuromodulation devices.
Main Results:
- New medications include CGRP monoclonal antibodies, CGRP receptor antagonists, serotonin 5-HT1F agonists, and PACAP receptor monoclonal antibodies.
- FDA-approved non-invasive neuromodulation devices include transcranial magnetic stimulation, supraorbital transcutaneous nerve stimulation, and transcutaneous vagus nerve stimulation.
- Investigational neuromodulation devices show promising results for migraine treatment.
Conclusions:
- Emerging treatments offer new avenues for acute and preventive episodic migraine management.
- These advancements are expected to decrease migraine-related disability.
- The integration of novel pharmacologic and device-based therapies is key to future migraine care.
Related Concept Videos
Emerging Adulthood
Introduction Cardiac Emergencies
Applications of GIS: Disaster Management and Emergency Response
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Treatment Resistant Cancers
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

